NCT04838405CompletedPhase 1
A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus
A Phase 1 Randomized, Double Blind, Placebo Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CT-388 in Otherwise Healthy Overweight and Obese Adult Participants and in Obese Patients With Type 2 Diabetes Mellitus
Source: ClinicalTrials.gov · Last updated 20 Oct 2025
Brief summary (registry, in English)
This is a first-in-human evaluation of CT-388 in a double blind, placebo controlled, randomized, SAD/MAD/MD, safety, tolerance, PK, and PD study when administered as a SC injection in otherwise healthy overweight and obese adult participants and obese participants with T2DM.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 129 (actual)
- First submitted
- 5 Apr 2021
- Start date
- 29 Apr 2021
- Primary completion date
- 18 Jun 2024
- Lead sponsor
- Carmot Therapeutics, Inc.
- Diseases
- Obesity, Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT04838405
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 129
- From 29 Apr 2021 to the primary completion date, 18 Jun 2024
- 2 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Uncontrolled hypertension
- History of malignancy
Other
- Significant medical history
Who the study is looking for
- Males or females
- 18-65 years old, inclusive
- BMI 27.0-40.0, inclusive
- Stable body weight for 2 months
Age in the registry: 18 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Carmot Clinical Research Unit 101 Coordinator of this site? Confirm its status | Perth | Australia | Unknown status |
| Carmot Clinical Research Unit 105 Coordinator of this site? Confirm its status | Monterrey | Mexico | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.